Therapeutic implications of the PP2A/MET signalling axis in doxorubicin-induced cardiotoxicity and antitumour properties

Br J Pharmacol. 2020 Aug;177(16):3850-3851. doi: 10.1111/bph.15130. Epub 2020 Jun 14.

Authors

Ion Cristóbal^{1

2}, Jaime Rubio^{1

2}, Andrea Santos^{1

2}, Melani Luque³, Marta Sanz-Alvarez³, Federico Rojo³, Jesús García-Foncillas^{1

2}

Affiliations

¹ Cancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain.
² Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Madrid, Spain.
³ Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Madrid, Spain.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cardiotoxicity*
Doxorubicin* / adverse effects
Humans
Signal Transduction

Substances

Doxorubicin